Stemline Therapeutics, Inc.: 3 clinical stage oncology product candidates. 1) ELZONRIS is a targeted therapy directed to IL-3 receptor (CD123) present on range of malignancies that successfully completed a pivotal trial in BPDCN and was granted breakthrough designation; BLA accepted, granted FDA priority review, PDUFA date of Feb 21, 2019. ELZONRIS also evaluated in chronic myelomonocytic leukemia, myelofibrosis et al. 2) SL-801 is an oral small molecule reversible inhibitor of XPO1 in Ph 1 trial of pts w advanced solid tumors. 3) SL-701 is an immunotherapeutic that completed Ph 2 trial in pts w/2nd line GBM.
Website:
Address:
750 Lexington Ave
11th Floor
New York, NY 10022
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.